Changeflow GovPing Government & Legislation Lei Yin Study: Children with Amalgam Show Eleva...
Priority review Notice Added Final

Lei Yin Study: Children with Amalgam Show Elevated Mercury

Favicon for www.regulations.gov Regulations.gov Final Notices
Published
Detected
Email

Summary

FDA has posted a study by Lei Yin to its public docket on Regulations.gov, docket FDA-2026-P-4271-0036. The study examines mercury levels in children with dental amalgam restorations. The document was published as a final notice on January 8, 2026. The full study content is restricted due to copyright.

Published by FDA on regulations.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

This feed pulls every final notice posted to regulations.gov across all federal agencies, around 240 a month. Final notices are the binding step in the federal rulemaking cycle: a final rule, a no-action determination, a self-regulatory organization rule change, or a procedural notice that takes effect on publication. Watch this for the actionable end of the rulemaking pipeline rather than the proposed-and-comment phase. GovPing publishes each notice with the issuing agency, docket ID, effective date where stated, and document type. Recent examples include Nasdaq ISE auction rule changes and an NYSE proposal enabling tokenized securities trading under the DTC pilot.

What changed

FDA has posted the Lei Yin study to its public docket on Regulations.gov under docket number FDA-2026-P-4271-0036. The study examines mercury levels in children with dental amalgam restorations and reports findings of elevated mercury in the pediatric population studied. The document was published as a final notice on January 8, 2026.

Affected parties, including dental professionals, public health authorities, and manufacturers of dental amalgam products, should monitor this docket for related filings and any subsequent FDA regulatory activity that may arise from these study findings.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Content

Content Restricted

Reason Restricted: Copyrighted

Get daily alerts for Regulations.gov Final Notices

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
FDA
Published
January 8th, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Docket
FDA-2026-P-4271-0036

Who this affects

Applies to
Healthcare providers Patients
Industry sector
6211 Healthcare Providers
Activity scope
Pediatric health study Dental material safety
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Clinical Operations
Topics
Public Health Medical Devices

Get alerts for this source

We'll email you when Regulations.gov Final Notices publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!